Walleye Trading
AVDL

Walleye Trading’s Avadel Pharmaceuticals AVDL Stock Holding History

Walleye Trading’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,154
Closed -$31.9K – 3971
2019
Q4 		$31K Sell
4,154
-26,924
-87% -$142K ﹤0.01% 3909
2019
Q3 		$129K Buy
+31,078
New +$77.8K ﹤0.01% 3205
2018
Q4 		– Sell
-3,000
Closed -$13K – 4604
2018
Q3 		$13K Buy
+3,000
New +$16.2K ﹤0.01% 4941
2017
Q4 		– Sell
-32,000
Closed -$336 – 4328
2017
Q3 		$336 Buy
32,000
+3,100
+11% +$29.6K ﹤0.01% 2827
2017
Q2 		$319 Buy
28,900
+22,300
+338% +$224K ﹤0.01% 2763
2017
Q1 		$64 Sell
6,600
-6,400
-49% -$64K ﹤0.01% 3659
2016
Q4 		$135K Sell
13,000
-300
-2% -$3.3K ﹤0.01% 3063
2016
Q3 		$165K Buy
13,300
+10,100
+316% +$132K ﹤0.01% 2956
2016
Q2 		$34K Sell
3,200
-8,600
-73% -$91.7K ﹤0.01% 4231
2016
Q1 		$130K Buy
+11,800
New +$117K ﹤0.01% 3126
2015
Q4 		– Sell
-3,000
Closed -$49K – 5260
2015
Q3 		$49K Buy
+3,000
New +$66.1K ﹤0.01% 3515

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Walleye Trading's AVDL Position: Q1 2020 in Review

Walleye Trading sold out of Avadel Pharmaceuticals (AVDL) in Q1 2020, closing a stake of 4,154 shares — an estimated $31.9K sold.

Walleye Trading first reported a position in AVDL in Q3 2015 and held it in 11 quarters. The position peaked at $165K in Q3 2016. 56 funds tracked by Wall St. Rank hold AVDL as of Q1 2020.

  • Walleye Trading reported no remaining Avadel Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Walleye Trading sold 4,154 Avadel Pharmaceuticals shares in Q1 2020, an estimated $31.9K.
  • Walleye Trading first reported a position in Avadel Pharmaceuticals in Q3 2015 and held it in 11 quarters.
  • Walleye Trading's Avadel Pharmaceuticals position peaked at $165K in Q3 2016.
  • 56 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2020.

Based on Walleye Trading's 13F filing for Q1 2020, filed 15 May 2020.